The sale gives Dendreon better access to capital for expansion and deals, its top executive said—perhaps into CAR-T or other cell therapies, an area where the company is already eyeing deals.
In this week's FiercePharmaAsia wrap-up, Astellas terminated an unfruitful vaccine deal, Takeda made a rare disease R&D pact, China's Sanpower has to deal with costly Provenge manufacturing, and more.
With its $830 million deal to buy Dendreon, Chinese conglomerate Sanpower Group takes on the expensive process of manufacturing prostate cancer vaccine Provenge.
